Rani Therapeutics (RANI) News Today $2.85 +0.60 (+26.67%) Closing price 04:00 PM EasternExtended Trading$3.21 +0.36 (+12.67%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Rani Therapeutics Up Today?Toggle Visibility of Why Is Rani Therapeutics Up Today?Rani Therapeutics Holdings, Inc. (RANI) — Shares have moved higher today after a wave of bullish analyst notes, a major partner deal and heavy bullish options activity. Investors appear to be pricing in the commercial partnership with Chugai, fresh financing and upgraded price targets. Positive Sentiment: HC Wainwright reaffirmed a "buy" and set an $11.00 price target (implies large upside vs. the current price), reinforcing analyst optimism. HC Wainwright Reaffirms Buy Rating for Rani Therapeutics (NASDAQ:RANI) Positive Sentiment: Maxim Group raised its price target to $10 (from $5) and reiterated a buy, adding further upward pressure from the sell‑side. Maxim Group Issues Positive Forecast for Rani Therapeutics (NASDAQ:RANI) Stock Price Positive Sentiment: Analysts at Seeking Alpha initiated coverage at Buy, citing the landmark Chugai collaboration (~$1.085B scope), positive preclinical R&D (RT‑114) and an oversubscribed $60.3M private placement that extends runway into 2028 — fundamental catalysts that support higher valuation. Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai Positive Sentiment: Unusually large options activity — ~37,490 call options bought in one day (4,337% above average) — signals speculative bullish positioning that can amplify short‑term upside. Rani Therapeutics Target of Unusually Large Options Trading (NASDAQ:RANI) Neutral Sentiment: MarketBeat notes the consensus across five analysts is an average "Moderate Buy" (four buys, one sell) — broadly positive but not unanimous. Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Rating of "Moderate Buy" by Analysts Negative Sentiment: High volatility and heavy retail/options flow have produced dramatic price swings (recent multi‑day surge tied to the Chugai deal); this raises the risk of sharp pullbacks and speculative squeezes — investors should be aware of execution and commercialization risks despite the positive headlines. Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost Bottom line for investors: bullish analyst upgrades, the Chugai collaboration and strong options buying are driving today’s upside, but the move is highly news‑driven and volatile—suitable for investors who can tolerate event‑driven risk. Posted 1h agoAI Generated. May Contain Errors. RANI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period HC Wainwright Reaffirms Buy Rating for Rani Therapeutics (NASDAQ:RANI)October 21 at 8:18 AM | marketbeat.comMaxim Group Maintains Rani Therapeutics Holdings (RANI) Buy RecommendationOctober 21 at 5:46 AM | msn.comRani Therapeutics price target raised to $10 from $5 at MaximOctober 21 at 5:46 AM | msn.comRani Therapeutics Target of Unusually Large Options Trading (NASDAQ:RANI)October 20 at 5:13 PM | marketbeat.comRani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With ChugaiOctober 20 at 3:12 PM | seekingalpha.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Rating of "Moderate Buy" by AnalystsOctober 20 at 1:47 PM | marketbeat.comMaxim Group Issues Positive Forecast for Rani Therapeutics (NASDAQ:RANI) Stock PriceOctober 20 at 1:36 PM | marketbeat.comTrending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&MOctober 20 at 11:10 AM | uk.finance.yahoo.comBiggest stock movers Monday: PLUG, RANI, and moreOctober 20 at 6:10 AM | msn.comRani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding BoostOctober 20 at 2:10 AM | finance.yahoo.comPenny Stocks To Watch Now - October 19thOctober 19 at 5:00 PM | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Increase in Short InterestOctober 19 at 10:14 AM | marketbeat.comPenny Stocks To Watch Now - October 17thOctober 18 at 5:14 PM | marketbeat.comRani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s ChangedOctober 18 at 2:41 PM | finance.yahoo.comRani Therapeutics stock soars after inking $1 billion potential deal with ChugaiOctober 18 at 3:15 AM | investing.comWhy Rani Therapeutics (RANI) Stock Is Soaring Friday?October 17, 2025 | uk.finance.yahoo.comRani Therapeutics Holdings, Inc. Stock (RANI) Opinions on $1.085 Billion Chugai CollaborationOctober 17, 2025 | quiverquant.comQRani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai PharmaOctober 17, 2025 | reuters.comRani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq RulesOctober 17, 2025 | globenewswire.comRani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million FinancingOctober 17, 2025 | globenewswire.comBiotech Innovators Drive the Future of Next-Generation TherapeuticsSeptember 29, 2025 | msn.comRani Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comRANI: Second Quarter Financial ResultsAugust 12, 2025 | finance.yahoo.comRani (RANI) Q2 Net Loss Improves 16%August 9, 2025 | theglobeandmail.comRani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate UpdateAugust 7, 2025 | globenewswire.comRani Therapeutics Holdings, Inc. (RANI) - Yahoo FinanceJuly 18, 2025 | finance.yahoo.comRani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering AnnouncementJuly 15, 2025 | msn.comRani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingJuly 15, 2025 | globenewswire.comRani Therapeutics Shares Surge After ENDO 2025 Presentation AnnouncementJuly 14, 2025 | msn.comRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryJuly 14, 2025 | globenewswire.comRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13, 2025 | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comRani Therapeutics (RANI) Expected to Announce Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Buy" from AnalystsApril 26, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)April 23, 2025 | markets.businessinsider.comRani Therapeutics management to meet virtually with Lake StreetApril 17, 2025 | markets.businessinsider.comWhat is Zacks Small Cap's Estimate for RANI FY2025 Earnings?April 5, 2025 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Earns "Buy" Rating from HC WainwrightApril 5, 2025 | marketbeat.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comRani Therapeutics (NASDAQ:RANI) Releases Earnings Results, Misses Estimates By $0.03 EPSApril 2, 2025 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPSApril 2, 2025 | marketbeat.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comRani Therapeutics reports Q4 EPS (27c), consensus (23c)April 1, 2025 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comRani Therapeutics Reports 2024 Financial Results and UpdatesMarch 31, 2025 | tipranks.com Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RANI Media Mentions By Week RANI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼0.410.50▲Average Medical News Sentiment RANI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼332▲RANI Articles Average Week Get the Latest News and Ratings for RANI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Rani Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TIL News ABOS News ZYBT News SPRO News CNTX News TCRX News VTGN News HURA News CLYM News IKT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.